Subscribe to the World's Most Popular Newsletter (it's free!)
Recombinant outer surface protein A (OspA) of Borrelia burgdorferi is a highly protective immunogen for prevention of
Lyme disease in experimental animals. Humoral immunity is sufficient for protection. The principal mechanism of action is prevention of transmission of the spirochete from tick to host. A recombinant OspA vaccine has been licensed for use in dogs. The recent licensure of an OspA vaccine for humans resulted from a critical analysis of recently completed efficacy studies.